Ankit Patel, DO
Interventional Pain Medicine · Phoenix, AZNPI 1831535350
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,251 of the $8,240 with a category attached, or 88.0%. 21 manufacturers reported payments, led by Abbott at 31.8% of the total. Reporting peaked in 2020 at $1,945 and has fallen 67.2% since, to $639 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in AZ, where the typical reported total is $8,993.
Across 249 payments — averaging $33.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Boston Scientific$1K
- Vertiflex, Inc.$1K
- Nevro Corp.$1K
- Medtronic$836
- Saluda Medical Americas, Inc.$292
- plus $948 from 15 others
What the payments were for
- Travel & lodging$93911%
- Food & beverage$7,25188%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 73 | $2,618 |
| Boston Scientific | 36 | $1,226 |
| Vertiflex, Inc. | 8 | $1,162 |
| Nevro Corp. | 55 | $1,159 |
| Medtronic(2 entities) | 25 | $836 |
| Saluda Medical Americas, Inc. | 20 | $292 |
| Spinal Simplicity, LLC | 5 | $198 |
| Globus Medical | 6 | $169 |
| Stryker | 2 | $146 |
| Painteq LLC | 5 | $91 |
| SPR Therapeutics, Inc | 2 | $62 |
| Fidia Pharma USA Inc. | 2 | $55 |
| Nalu Medical, Inc. | 2 | $49 |
| Averitas Pharma Inc. | 1 | $31 |
| Electronic Waveform Lab, Inc. | 1 | $29 |
| Pfizer | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Medline Industries LP | 1 | $16 |
| International Rehabilitative Sciences, Inc | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Superion ISS$939
- Proclaim IPG$644
- Proclaim Family of SCS IPGs$500
- PROCLAIM$495
- INTELLIS ADAPTIVESTIM$316
- SPECTRA WAVEWRITER$276
- HA MINUTEMAN G3-R$156
- Neuromodulation Dspsbls and Accs$143
- Senza$137
- mild Device Kit$129
- FIXATE$118
- ENTRADA$116
- Omnia$111
How this compares
$8,240 in reported general payments places this provider in the 45th percentile of 64 interventional pain medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 474 | $15,710 |
| Oxycodone Hcl | 623 | $10,975 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 274 | $7,542 |
| LyricaPregabalin | 13 | $7,293 |
| Gabapentin | 243 | $3,420 |
| Tramadol Hcl | 272 | $2,330 |
| Methocarbamol | 118 | $1,965 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 88 | $1,411 |
| Tizanidine Hcl | 146 | $1,277 |
| Cyclobenzaprine Hcl | 144 | $1,181 |
| Celecoxib | 59 | $1,099 |
| Pregabalin | 72 | $965 |
| Ibuprofen | 58 | $797 |
| Meloxicam | 132 | $465 |
| Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen | 58 | $438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerLyrica | $28 | $7,29313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 64 interventional pain medicine providers in Arizona.
Other interventional pain medicine in Phoenix
- Steven SiwekPhoenix$57K
- Ramoun JonesPhoenix$51K
- Lisa StearnsPhoenix$48K
- Jerome GrovePhoenix$21K
- Thomas MoshiriPhoenix$19K
- Abram BurgherPhoenix$15K
- Adam SiwekPhoenix$14K
- Todd TurleyPhoenix$13K
- Jarrett LeathemPhoenix$11K
- Chhavi ManchandaPhoenix$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.